Table 2 Incidence of new-onset grade 3 or 4 nonhematologic adverse events in the ruxolitinib group regardless of causality, grouped by treatment time interval
|  | Ruxolitinib (n = 155) | ||||
|---|---|---|---|---|---|
0– < 12 Months | 12– < 24 Months | 24– < 36 Months | 36– < 48 Months | ≥48 Months | |
Event,*n/N (%) | |||||
 Fatigue | 9/144.5 (6.2) | 1/113.0 (0.9) | 3/90.0 (3.3) | 1/69.5 (1.4) | 0 |
 Pneumonia | 8/144.0 (5.6) | 4/112.0 (3.6) | 3/86.0 (3.5) | 2/67.5 (3.0) | 5/32.0 (15.6) |
 Abdominal pain | 6/143.5 (4.2) | 0 | 3/93.5 (3.2) | 1/72.5 (1.4) | 1/32.0 (3.1) |
 Arthralgia | 3/142.5 (2.1) | 0 | 0 | 1/70.0 (1.4) | 0 |
 Diarrhea | 3/143.5 (2.1) | 0 | 0 | 1/72.5 (1.4) | 0 |
 Dyspnea | 3/143.5 (2.1) | 1/116.5 (0.9) | 2/92.5 (2.2) | 1/71.5 (1.4) | 1/31.5 (3.2) |
 Pain in extremity | 3/142.5 (2.1) | 0 | 1/89.5 (1.1) | 1/69.5 (1.4) | 1/30.5 (3.3) |
 Acute myeloid leukemia | 2/143.5 (1.4) | 0 | 1/93.0 (1.1) | 2/74.0 (2.7) | 0 |
 Fall | 2/142.5 (1.4) | 1/114.5 (0.9) | 0 | 2/71.0 (2.8) | 1/30.5 (3.3) |
 Gastrointestinal hemorrhage | 2/142.5 (1.4) | 1/115.0 (0.9) | 0 | 0 | 0 |
 Hyperuricemia | 2/142.5 (1.4) | 1/114.5 (0.9) | 0 | 1/71.5 (1.4) | 0 |
 Hypoxia | 2/142.5 (1.4) | 0 | 2/92.0 (2.2) | 0 | 1/31.5 (3.2) |
 Muscular weakness | 2/143.0 (1.4) | 0 | 1/91.5 (1.1) | 0 | 0 |
 Septic shock | 2/143.5 (1.4) | 0 | 0 | 0 | 0 |
 Acute renal failure | 1/142.5 (0.7) | 1/116.0 (0.9) | 3/93.0 (3.2) | 2/72.5 (2.8) | 1/31.5 (3.2) |
 Back pain | 1/142.5 (0.7) | 2/116.0 (1.7) | 0 | 0 | 0 |
 Congestive cardiac failure | 1/142.5 (0.7) | 0 | 1/92.0 (1.1) | 0 | 2/32.5 (6.2) |
 Epistaxis | 1/143.0 (0.7) | 2/117.0 (1.7) | 0 | 0 | 0 |
 Sepsis | 1/143.0 (0.7) | 2/116.5 (1.7) | 2/92.5 (2.2) | 1/73.0 (1.4) | 2/32.5 (6.2) |
 Upper abdominal pain | 1/143.0 (0.7) | 0 | 2/92.5 (2.2) | 0 | 0 |
 Cellulitis | 0 | 0 | 0 | 2/73.5 (2.7) | 0 |
 Myocardial infarction | 0 | 1/117.0 (0.9) | 0 | 2/73.5 (2.7) | 0 |
 Osteoarthritis | 0 | 0 | 1/92.5 (1.1) | 0 | 2/32.5 (6.2) |
 Osteomyelitis | 0 | 0 | 0 | 2/73.0 (2.7) | 0 |
 Squamous cell carcinoma | 0 | 1/116.5 (0.9) | 0 | 0 | 2/32.5 (6.2) |
 Urinary tract infection | 0 | 1/116.5 (0.9) | 1/92.0 (1.1) | 0 | 2/33.0 (6.1) |
 Wound infection | 0 | 0 | 0 | 0 | 2/33.0 (6.1) |